<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001064</url>
  </required_header>
  <id_info>
    <org_study_id>SPIRAT 1</org_study_id>
    <nct_id>NCT00001064</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells &gt; 350 Cells/mm3</brief_title>
  <official_title>A Pilot Study of Immunization With HIV-1 Antigen Pulsed Allogenic Dendritic Cells in HIV-Infected Asymptomatic Patients With CD4+ T Cells &gt; 350 Cells/mm3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To define the safety and efficacy of sibling-supplied, HIV antigen-pulsed dendritic cells in&#xD;
      increasing the immune response in HIV-infected patients.&#xD;
&#xD;
      Dendritic cells are a type of white blood cell used by the body to fight infection. They are&#xD;
      instrumental in presenting antigens (such as HIV antigens) to the body's immune system. Since&#xD;
      dendritic cells are not functioning maximally in HIV-infected patients, infusion of dendritic&#xD;
      cells from an HIV-negative sibling may enable the affected sibling's immune system to&#xD;
      recognize foreign particles more readily and increase immune response against the virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dendritic cells are a type of white blood cell used by the body to fight infection. They are&#xD;
      instrumental in presenting antigens (such as HIV antigens) to the body's immune system. Since&#xD;
      dendritic cells are not functioning maximally in HIV-infected patients, infusion of dendritic&#xD;
      cells from an HIV-negative sibling may enable the affected sibling's immune system to&#xD;
      recognize foreign particles more readily and increase immune response against the virus.&#xD;
&#xD;
      Dendritic cells from an HIV-negative sibling are obtained and treated with various viral&#xD;
      proteins (HIV vaccines) or immunomodulators. The treated dendritic cells are infused into the&#xD;
      HIV-infected patient monthly for 6 months. Siblings must be able to donate on multiple&#xD;
      occasions, and patients are followed every 2-4 weeks during the study. Patients are screened&#xD;
      over 3 months prior to study entry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogenic Dendritic Cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HLA A2+.&#xD;
&#xD;
          -  Same cell type as donor sibling.&#xD;
&#xD;
          -  CD4 count &gt; 350 cells/mm3.&#xD;
&#xD;
          -  HIV asymptomatic status.&#xD;
&#xD;
          -  No HIV antivirals during study.&#xD;
&#xD;
          -  Normal labs and chest x-ray.&#xD;
&#xD;
        Donor siblings must have:&#xD;
&#xD;
          -  HLA A2+.&#xD;
&#xD;
          -  HIV negativity.&#xD;
&#xD;
          -  Ability to donate cells on multiple occasions.&#xD;
&#xD;
          -  Negative status for hepatitis B and C.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiviral therapy (unless CD4 count declines to &lt; 350 cells/mm3).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiviral therapy within 90 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford Univ School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>943055107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <keyword>HIV Antigens</keyword>
  <keyword>Immunotherapy, Adoptive</keyword>
  <keyword>Dendritic Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

